ERBB2 and breast carcinoma: Moreover, through analyses of tumor microarray data linked to therapy response of cancer patients, we found that high expression of NSMCE2 predicts poor response to chemotherapeutic drugs for patients diagnosed with breast cancer, especially patients diagnosed with aggressive TN or HER2 + tumors.